Canadian liver journal最新文献

{"title":"Impact of decompensated cirrhosis in children: A population-based study.","authors":"Mohit Kehar,&nbsp;Rebecca Griffiths,&nbsp;Jennifer A Flemming","doi":"10.3138/canlivj-2022-0031","DOIUrl":"https://doi.org/10.3138/canlivj-2022-0031","url":null,"abstract":"<p><strong>Background: </strong>We describe the proportion of children with compensated cirrhosis who develop decompensation in Ontario, Canada over the past two decades.</p><p><strong>Methods: </strong>This is a retrospective population-based cohort study using routinely collected health care data from Ontario, Canada held at ICES during 1997-2017. Diagnosis of cirrhosis was made using validated ICES definition, and decompensation events were defined according to validated coding. Rates of decompensation, type of decompensation, and incidence of liver transplantation after decompensation were analyzed. Databases were linked at the individual level and analyzed at ICES-Queen's.</p><p><strong>Results: </strong>A total of 2,755 children with compensated cirrhosis were included and 9% (253) developed decompensation over a median follow-up of 7 years. Children most likely to suffer decompensation were younger (median age 10 versus 4 years, <i>p</i> < 0.001) and female (45% versus 52%, <i>p</i> = 0.03). Ascites (137/253, 54%) was the most frequent complication. 199/2755 (7%) of children with cirrhosis received liver transplantation, of which 64% (128/199) occurred after a decompensation event. Overall, a total of 132 (4.7%) deaths occurred during the study period, with 55 deaths following a decompensating event.</p><p><strong>Conclusion: </strong>We present the first study to describe rates of decompensation, type, and rate of liver transplantation after decompensation in pediatric cirrhosis at the population level. To improve the care of children with liver disease, early detection of liver disease, early initiation of specific treatments as well as identification of children who are at risk of becoming decompensated are crucial.</p>","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 2","pages":"278-282"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370729/pdf/canlivj-2022-0031.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10264281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exception points for liver transplantation: A Canadian review.","authors":"Stephen E Congly,&nbsp;Vladimir Marquez,&nbsp;Rahima A Bhanji,&nbsp;Mamatha Bhat,&nbsp;Philip Wong,&nbsp;Geneviève Huard,&nbsp;Julie H Zhu,&nbsp;Mayur Brahmania","doi":"10.3138/canlivj-2022-0026","DOIUrl":"https://doi.org/10.3138/canlivj-2022-0026","url":null,"abstract":"<p><strong>Background: </strong>Exception points for liver transplant (LT) allocation are used to account for mortality risk not reflected by scoring systems such as the Model for End-Stage Liver Disease with sodium (MELD-Na). Currently, there is no formal policy regarding exception points in Canada, and differences across the country are not well understood. As such, a review of the criteria and exception points granted throughout the country for LT was conducted.</p><p><strong>Methods: </strong>Seven LT centres in five provinces were surveyed (Vancouver, Edmonton, London, Toronto, Montréal, Halifax) regarding the indications and criteria for exception points granted, the number of points granted, how points would be accrued, and the maximum points granted.</p><p><strong>Results: </strong>Programs in British Columbia and Nova Scotia grant variable exception points based on the median MELD-Na score with modifications; Alberta, Ontario, and Quebec grant exception points using specific values based on the indication. Overall, there was significant heterogeneity regarding exception points granted nationally with agreement only for awarding exception points for hepatopulmonary syndrome and polycystic liver disease. The second most common agreed-upon indications for exception points were portopulmonary hypertension and recurrent cholangitis offered by four provinces. Quebec had the most formal criteria for non-cirrhosis-based conditions.</p><p><strong>Conclusions: </strong>There is substantial variance across the country regarding the indications for granting exception points as well as the number of points granted. Future work on developing a national consensus will be important for the development of equity in LT across Canada.</p>","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 2","pages":"201-214"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370721/pdf/canlivj-2022-0026.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10264282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post liver transplantation delirium assessment using the CAM-ICU-7 scale: A cohort analysis.","authors":"Filipe S Cardoso,&nbsp;Beverley Kok,&nbsp;Victor Dong,&nbsp;Minjee Kim,&nbsp;Constantine J Karvellas","doi":"10.3138/canlivj-2022-0037","DOIUrl":"https://doi.org/10.3138/canlivj-2022-0037","url":null,"abstract":"<p><strong>Background: </strong>We applied the Confusion Assessment Method (CAM)-Intensive Care Unit (ICU)-7 delirium scale to patients who underwent liver transplant (LT).</p><p><strong>Methods: </strong>Retrospective cohort including patients who underwent LT for cirrhosis admitted to the ICU from June 2013 to June 2016 at the University of Alberta Hospital, Canada. Delirium was assessed using the CAM-ICU-7 scale (0-7 points) twice daily on days one and 3 post LT, with the highest score being considered. Primary endpoint was hospital mortality.</p><p><strong>Results: </strong>Among all patients, 101/150 (67.3%) were men and mean age was 52.4 (SD 11.8) years. On days 1 and 3 post LT, mean CAM-ICU-7 scores were 1.8 (SD 1.3) and 1.6 (SD 1.8), respectively. Therefore, on days 1 and 3 post LT, 38/150 (25.3%) and 26/95 (27.4%) patients had delirium. While delirium on day 3 post LT was associated with higher hospital mortality (11.5% versus 0%; <i>p</i> = 0.019), it was not associated with length-of-hospital stay (29.2 versus 34.4 days; <i>p</i> = 0.36). Following adjustment for APACHEII score, delirium on day 3 post LT was associated with higher odds of hospital mortality (adjusted odds ratio [aOR] 1.89 [95% CI 1.02-3.50]). Following adjustment for Glasgow Coma Scale and mechanical ventilation, serum creatinine was associated with higher odds of delirium on day 3 post LT (aOR 2.02 [95% CI 1.08-3.77]).</p><p><strong>Conclusions: </strong>Using the CAM-ICU-7 scale, delirium was diagnosed in a fourth of patients who underwent LT. Delirium on day 3 post LT was associated with higher odds of hospital mortality.</p>","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 2","pages":"261-268"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370723/pdf/canlivj-2022-0037.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Annual trends of hepatitis C virus infection in Manitoba between 1998 and 2018: A focus on special populations.","authors":"Sai Krishna Gudi,&nbsp;Sherif Eltonsy,&nbsp;Joseph Delaney,&nbsp;Carla Osiowy,&nbsp;Carole Taylor,&nbsp;Kelly Kaita,&nbsp;Silvia Alessi-Severini","doi":"10.3138/canlivj-2022-0030","DOIUrl":"https://doi.org/10.3138/canlivj-2022-0030","url":null,"abstract":"<p><strong>Background: </strong>Hepatitis C virus (HCV) infection is a major cause of liver-related morbidity and mortality worldwide. Epidemiological data of HCV infection in the Canadian province of Manitoba are limited.</p><p><strong>Methods: </strong>A population-based retrospective study was conducted using data from the Manitoba Centre for Health Policy repository. Using the test results provided by the Cadham provincial laboratory, individuals in Manitoba with a diagnosis of HCV infection were identified. Annual prevalence and incidence rates (crude and standardized) were calculated for the overall population and stratified by sex, regional health authority (RHA), residence area, income quintile, and special population groups (children, older adults, and pregnant persons).</p><p><strong>Results: </strong>A total of 8,721 HCV cases were diagnosed between 1998 and 2018 in Manitoba. Overall crude HCV incidence and prevalence were estimated as 0.03% and 0.37% during the study period, respectively. No significant change was observed in the standardized HCV incidence rate (per 100,000) during the study period (54.3 in 1998 and 54.8 in 2018). However, the standardized HCV prevalence (per 100,000) increased from 52.5 (95% CI 39.2-68.7) in 1998 to 655.2 (95% CI 605.9-707.3) in 2018. An overall average incidence rate based on sex, RHA, region, income, and special population groups was observed to be higher in males (40.1), Winnipeg RHA (42.7), urban region (42.3), low-income quintiles (78.5), and pregnant persons (94.3), respectively.</p><p><strong>Conclusion: </strong>Although incidence rates of HCV infection in Manitoba appeared to have initially declined, rates showed an upward trend by the end of the study period while prevalence increased steadily.</p>","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 2","pages":"249-260"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370720/pdf/canlivj-2022-0030.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10264278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.","authors":"Gaelen Snell,&nbsp;Alison D Marshall,&nbsp;Jennifer van Gennip,&nbsp;Matthew Bonn,&nbsp;Janet Butler-McPhee,&nbsp;Curtis L Cooper,&nbsp;Nadine Kronfli,&nbsp;Sarah Williams,&nbsp;Julie Bruneau,&nbsp;Jordan J Feld,&nbsp;Naveed Z Janjua,&nbsp;Marina Klein,&nbsp;Nance Cunningham,&nbsp;Jason Grebely,&nbsp;Sofia R Bartlett","doi":"10.3138/canlivj-2022-0040","DOIUrl":"https://doi.org/10.3138/canlivj-2022-0040","url":null,"abstract":"<p><strong>Background: </strong>Direct-acting antiviral (DAA) therapies have simplified HCV treatment, and publicly funded Canadian drug plans have eliminated disease-stage restrictions for reimbursement of DAA therapies. However other policies which complicate, delay, or prevent treatment initiation still persist. We aim to describe these plans' existing reimbursement criteria and appraise whether they hinder treatment access.</p><p><strong>Methods: </strong>We reviewed DAA reimbursement policies of 16 publicly funded drug plans published online and provided by contacts with in-depth knowledge of prescribing criteria. Data were collected from May to July 2022. Primary outcomes were: (1) if plans have arranged to accept point-of-care HCV RNA testing for diagnosis; testing requirements for (2) HCV genotype, (3) fibrosis stage, and (4) chronic infection; (5) time taken and method used to approve reimbursement requests; (6) providers eligible to prescribe DAAs; and (7) restrictions on re-treatment.</p><p><strong>Results: </strong>Fifteen (94%) plans have at least one policy in place which limits simplified HCV treatment. Many plans continue to require results of genotype or fibrosis staging, limit eligible prescribers, and take longer than 1 day to approve coverage requests. One plan discourages treatment for re-infection.</p><p><strong>Conclusion: </strong>Reimbursement criteria set by publicly funded Canadian drug plans continue to limit timely, equitable access to HCV treatment. Eliminating clinically irrelevant pre-authorization testing, expanding eligible prescribers, expediting claims processing, and broadening coverage of treatment for reinfection will improve access to DAAs. The federal government could further enhance efforts by introducing a federal HCV elimination strategy or federal high-cost drug PharmaCare program.</p>","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 2","pages":"190-200"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370724/pdf/canlivj-2022-0040.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10264280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in health utilities among hepatitis C patients receiving care in different settings.","authors":"Yasmin A Saeed, Kate Mason, Nicholas Mitsakakis, Jordan J Feld, Karen E Bremner, Arcturus Phoon, Alice Fried, Josephine F Wong, Jeff Powis, Murray D Krahn, William Wl Wong","doi":"10.3138/canlivj-2022-0009","DOIUrl":"10.3138/canlivj-2022-0009","url":null,"abstract":"<p><p><b>BACKGROUND:</b> Although chronic hepatitis C (CHC) disproportionately affects marginalized individuals, most health utility studies are conducted in hospital settings which are difficult for marginalized patients to access. We compared health utilities in CHC patients receiving care at hospital-based clinics and socio-economically marginalized CHC patients receiving care through a community-based program. <b>METHODS:</b> We recruited CHC patients from hospital-based clinics at the University Health Network and community-based sites of the Toronto Community Hep C Program, which provides treatment, support, and education to patients who have difficulty accessing mainstream health care. We elicited utilities using six standardized instruments (EuroQol-5D-3L [EQ-5D], Health Utilities Index Mark 2/Mark 3 [HUI2/HUI3], Short Form-6D [SF-6D], time trade-off [TTO], and Visual Analogue Scale [VAS]). Multivariable regression analysis was performed to examine factors associated with differences in health utility. <b>RESULTS:</b> Compared with patients recruited from the hospital setting (<i>n</i> = 190), patients recruited from the community setting (<i>n</i> = 101) had higher unemployment (87% versus 67%), history of injection drug use (88% versus 42%), and history of mental health issue(s) (79% versus 46%). Unadjusted health utilities were lower in community than hospital patients (e.g., EQ-5D: 0.722 [SD 0.209] versus 0.806 [SD 0.195]). Unemployment and a history of mental health issue(s) were significant predictors of low health utility. <b>CONCLUSIONS:</b> Socio-economically marginalized CHC patients have lower health utilities than patients typically represented in the CHC utility literature. Their utilities should be incorporated into future cost-utility analyses to better represent the population living with CHC in health policy decisions.</p>","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 1","pages":"24-38"},"PeriodicalIF":0.0,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997513/pdf/canlivj-2022-0009.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9453740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lessons from First Nations partnerships in hepatitis C research and the co-creation of knowledge.","authors":"Andrew B Mendlowitz,&nbsp;Karen E Bremner,&nbsp;Jordan J Feld,&nbsp;Lyndia Jones,&nbsp;Evelynne Hill,&nbsp;Elly Antone,&nbsp;Laura Liberty,&nbsp;Rene Boucher,&nbsp;Murray D Krahn","doi":"10.3138/canlivj-2022-0011","DOIUrl":"https://doi.org/10.3138/canlivj-2022-0011","url":null,"abstract":"<p><p><b>BACKGROUND:</b> Administrative health data provide a rich and powerful tool for health services research. Partnership between researchers and the Ontario First Nations HIV/AIDS Education Circle (OFNHAEC) allowed for comprehensive analyses of the health and economic impacts of hepatitis C virus (HCV) infection in First Nations populations across Ontario, using administrative data. Examples of meaningful involvement of First Nations partners in research using secondary data sources demonstrate how community-based participatory research principles can be adapted to empower First Nations stakeholders and decision-makers. The aim of this review is to summarize and reflect on lessons learned in producing meaningful and actionable First Nations HCV research using health administrative data, from the perspective of health services researchers who collaborated for the first time with First Nations partners. <b>METHODS:</b> We discuss how our relationship with OFNHAEC formed and how engagement contextualized findings and provided opportunities for fostering trust and mutual capacity building. Methods included adherence to data governance principles, agreements outlining ethical conduct, and establishing commitment between partners. <b>RESULTS:</b> Engagement with OFNHAEC enhanced cultural understandings in study conception, design, and analysis, and enabled meaningful lessons for both parties through contextualizing findings together. Partnership ensured attention to factors, such as strength-based approaches and limitations of administrative data in their representation of First Nations peoples, that are not considered in standard HCV health services research using administrative health data. <b>CONCLUSIONS:</b> Collaboration throughout the HCV research provided first-hand experience of the relevance, representation, and importance of incorporating First Nations perspectives in health services research using administrative data.</p>","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 1","pages":"46-55"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997512/pdf/canlivj-2022-0011.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9469547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Binge drinking does not appear to have an adverse effect on non-alcoholic fatty liver disease: Findings from a study of four First Nations communities.","authors":"Roman Dascal,&nbsp;Colin Rumbolt,&nbsp;Julia Uhanova,&nbsp;Daria Surina,&nbsp;Grace Oketola,&nbsp;Byron Beardy,&nbsp;Gerald Y Minuk","doi":"10.3138/canlivj-2022-0013","DOIUrl":"https://doi.org/10.3138/canlivj-2022-0013","url":null,"abstract":"<p><p><b>BACKGROUND:</b> Binge drinking and non-alcoholic fatty liver disease (NAFLD) are common health problems throughout the world. However, the impact of binge drinking on NAFLD has yet to be described. The objective of this study was to document the extent of liver disease in community-based NAFLD patients who self-reported monthly binge drinking and compare the findings to NAFLD patients from the same communities who denied binge drinking (controls). <b>METHODS:</b> The study was undertaken in four Manitoba First Nations communities where the sale and consumption of alcoholic beverages are prohibited but visits to urban centres are common. Binge drinkers were retrospectively matched 1:2 by age, sex, and body mass index (BMI) with controls. NAFLD was diagnosed by ultrasonographic features of excess fat in the liver in individuals with no alternative, non-metabolic explanation for fatty infiltration of the liver. Hepatic inflammation and function were determined by standard liver biochemistry testing and fibrosis by FIB-4 levels and hepatic elastography. <b>RESULTS:</b> Of 546 NAFLD patients, 88 (16%) attested to binge drinking. The mean age of binge drinkers was 40 (SD 13) years; 51% were male; and the mean BMI was 34 (SD 7). Compared with controls, binge drinkers had similar liver biochemistry results (alanine and aspartate aminotransferases: 41 [SD 39] and 36 [SD 30] versus 36 [SD 36] and 31 [SD 27] U/L, <i>p</i> = 0.35 and <i>p</i> = 0.37, respectively), FIB-4 values (0.75 [SD 0.55] versus 0.72 [SD 0.44], <i>p</i> = 0.41, respectively), and hepatic elastrography (6.6 [SD 3.9] versus 6.2 [SD 2.9] kPa, <i>p</i> = 0.37, respectively) findings. <b>CONCLUSIONS:</b> In this study population, monthly binge drinking did not appear to impact the severity of NAFLD.</p>","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 1","pages":"39-45"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997515/pdf/canlivj-2022-0013.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9453742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five years after….","authors":"Natasha Chandok,&nbsp;Eric M Yoshida","doi":"10.3138/canlivj-2022-12-12","DOIUrl":"https://doi.org/10.3138/canlivj-2022-12-12","url":null,"abstract":"","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 1","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997520/pdf/canlivj-2022-12-12.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9461245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Annual Meeting of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CANHEPC) and the Canadian Association of Hepatology Nurses (CAHN) 2023 Abstracts.","authors":"","doi":"10.3138/canlivj.6.1.abst","DOIUrl":"https://doi.org/10.3138/canlivj.6.1.abst","url":null,"abstract":"","PeriodicalId":9527,"journal":{"name":"Canadian liver journal","volume":"6 1","pages":"76-180"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997518/pdf/canlivj.6.1.abst.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9461244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}